Our objective is to create a cardiometabolic cohort that could be representative of the local population, consisting of Qataris and long-term residents, in order to identify the prevalence, risk factors, and clinical characteristics of cardiometabolic disorders, as well as the incidence of atherosclerotic cardiovascular disease events.
Qatar, along with other Gulf Cooperation Council (GCC) countries, experiences one of the highest rates of diabetes, obesity, and cardiovascular risk factors. However, the impact of those risk factors on cardiac diseases, in particular atherosclerotic cardiovascular disease (ASCVD), is not well studied. Further, the incidence of mortality in participants with diabetes and high cardiovascular risk is not known. We will conduct a prospective, longitudinal, observational cohort that investigates the natural history of cardiometabolic diseases in citizens and long-term residents in Qatar: the Qatar Cardiometabolic Cohort (QCMC). The cohort will examine the prevalence, risk factors, and characterization of cardiometabolic patients, as well as the incidence of mortality and ASCVD events.
Study Type
OBSERVATIONAL
Enrollment
3,000
Hamad Medical Corporation
Doha, Qatar
Comparison of the incidence of the of major adverse cardiovascular events between the three groups (control, pre-diabetes, and diabetes)
To compare the incidence of major adverse cardiovascular events (3-point MACE: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) across three groups of adults with established ASCVD or very high cardiovascular risk: non-diabetes, pre-diabetes, and type 2 diabetes.
Time frame: Baseline, Year 1, and Year 5
Change in body mass index (BMI)
Change in BMI (kg/m²) from baseline (Year 0) to Year 1 and Year 5.
Time frame: Baseline, Year 1, and Year 5
Change in waist-to-hip ratio
Change in waist-to-hip ratio from baseline (Year 0) at Year 1 and Year 5.
Time frame: Baseline, Year 1, and Year 5
Change in fasting glucose
Change in fasting glucose from baseline (Year 0) at Year 1 and Year 5.
Time frame: Baseline, Year 1, and Year 5.
Change in glycated hemoglobin (HbA1c)
Change in HbA1c (%) from baseline (Year 0) at Year 1 and Year 5.
Time frame: Baseline, Year 1, and Year 5
Change in lipid profile parameters
Parameters include total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Changes from baseline will be assessed at Year 1 and Year 5.
Time frame: Baseline, Year 1, and Year 5.
Change in systolic and diastolic blood pressure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in systolic and diastolic blood pressure (mmHg) from baseline (Year 0) at Year 1 and Year 5.
Time frame: Baseline, Year 1, and Year 5
Electrocardiogram (ECG) - Heart Rate
ECGs will be evaluated for clinically significant abnormalities. Changes from baseline in heart rate -beats per minute will be assessed at Year 1 and Year 5."
Time frame: Baseline, Year 1, and Year 5.
ECG - PR interval
ECGs will be evaluated for clinically significant abnormalities. Changes from baseline will be assessed in the PR interval (ms-milli second) at Year 1 and Year 5."
Time frame: Baseline, Year 1, and Year 5.
ECG - QTc interval
ECGs will be evaluated for clinically significant abnormalities in the QTc interval in ms-milliseconds. Changes from baseline will be assessed at Year 1 and Year 5."
Time frame: Baseline, Year 1, and Year 5
ECG- QRS Duration
ECGs will be evaluated for clinically significant abnormalities in the QRS duration (ms-milli second). Changes from baseline will be assessed at Year 1 and Year 5.
Time frame: Baseline, Year 1, and Year 5.
Liver Stiffness Measurement
Change in liver stiffness (kPa) assessed by Fibroscan from baseline (Year 0) at Year 1 and Year 5
Time frame: Baseline, Year 1, and Year 5
Controlled Attenuation Parameter
Quantitative measure obtained by FibroScan (transient elastography) that assesses hepatic steatosis (liver fat content)- Unit: decibels per meter (dB/m) by measuring ultrasound attenuation in the liver.
Time frame: Baseline, Year 1, and Year 5]
Left Ventricular Ejection Fraction - LVEF
Transthoracic echocardiography will be performed using standard imaging protocols. Parameters assessed will include left ventricular ejection fraction (LVEF, %).
Time frame: Baseline, Year 1, and Year 5.
Left Ventricular Mass Index
Transthoracic echocardiography will be performed using standard imaging protocols. Parameters assessed will include left ventricular mass index unit- (g/m²).
Time frame: Baseline, Year 1, and Year 5.
E/e' Ratio
Ratio of mitral inflow velocity to mitral annular tissue velocity; estimates left ventricular filling pressures and diastolic dysfunction severity assessed by Transthoracic echocardiography.
Time frame: Baseline, Year 1, and Year 5.
E/A Ratio
Ratio of early (E) to late (A) mitral inflow velocities; used to assess left ventricular diastolic filling pattern to be assessed by Transthoracic echocardiography.
Time frame: Baseline, Year 1, and Year 5.
Pulmonary Artery Systolic Pressure - PASP
Estimated pressure in the pulmonary artery derived from tricuspid regurgitation velocity; reflects pulmonary hypertension and right heart load will be measured using Transthoracic echocardiography in mmHg.
Time frame: Baseline, Year 1, and Year 5.
Tricuspid Annular Plane Systolic Excursion - TAPSE
Measure longitudinal movement of the tricuspid annulus, indicator of right ventricular systolic function in Transthoracic echocardiography unit mm.
Time frame: Baseline, Year 1, and Year 5.
Incidence of major adverse cardiovascular events (4-point MACE)
4-point MACE will be defined as a composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular mortality, and hospitalization for unstable angina
Time frame: Baseline (Year 0), Year 1, and Year 5
Incidence of new-onset cardiac diseases and cardiovascular revascularization procedures
New-onset cardiac diseases will include heart failure, atrial fibrillation or other arrhythmias, and valvular heart disease. Cardiovascular revascularization procedures will include coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI/PTCA), carotid angioplasty, carotid endarterectomy, and lower limb revascularization.
Time frame: Baseline (Year 0), Year 1, Year 5
Incidence of new non-cardiac diseases requiring hospitalization
This outcome includes the development of any new non-cardiac medical condition requiring hospital admission, excluding cardiovascular causes. Hospitalizations will be categorized by system (e.g., infectious, respiratory, renal, gastrointestinal, or other medical causes).
Time frame: Baseline (Year 0), Year 1, and Year 5